Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decoglurant in MDD with inadequate response
NCT01457677Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of Decoglurant in major depressive disorder (MDD) (4 arms), sponsored by Roche. Primary endpoint: Mean change in Montgomery Asberg Depression Rating Scale scores at 6 weeks. Started Dec 2011; status: completed.
02
Drugs
Decoglurant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01457677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457677.